Munch E P, Søborg M, Nørreslet T T, Mygind N
Allergy. 1983 Oct;38(7):517-24. doi: 10.1111/j.1398-9995.1983.tb02361.x.
It was the aim of the study to compare the efficacy and side effects of oral antihistamine and nasal glucocorticoid therapy in seasonal allergic, rhinitis. In a double blind, double-dummy, group-comparative study, 61 adult grass pollen allergic patients were either treated with dexchlorpheniramine maleate sustained release tablets (6 mg b.d.), or with budesonide nasal spray (200 micrograms b.d.). After a 1-week run-in period, treatment was given for 3 weeks in the grass pollen season. Patients treated with budesonide showed significantly less nasal blockage than those who received dexchlorpheniramine (P less than 0.05), but there was no difference in the number of sneezes and nose blowings. Patients treated with budesonide and a larger quantity of antihistamine-vasoconstrictor eye drops (P less than 0.01). Drowsiness occurred in the group that was treated with dexchlorpheniramine, but mainly during the first week of treatment. The side effects caused by the budesonide spray were few and insignificant. The patients' overall assessment of the treatment favoured the glucocorticoid spray (P = 0.06).
本研究旨在比较口服抗组胺药和鼻用糖皮质激素治疗季节性过敏性鼻炎的疗效和副作用。在一项双盲、双模拟、组间比较研究中,61名成年草花粉过敏患者分别接受马来酸氯苯那敏缓释片(每日2次,每次6毫克)或布地奈德鼻喷雾剂(每日2次,每次200微克)治疗。经过1周的导入期后,在草花粉季节进行3周的治疗。接受布地奈德治疗的患者鼻塞症状明显少于接受氯苯那敏治疗的患者(P<0.05),但打喷嚏和擤鼻次数无差异。接受布地奈德治疗的患者使用的抗组胺-血管收缩剂眼药水数量更多(P<0.01)。氯苯那敏治疗组出现嗜睡,但主要在治疗的第一周。布地奈德喷雾剂引起的副作用很少且不明显。患者对治疗的总体评价倾向于糖皮质激素喷雾剂(P=0.06)。